Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD
Aurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The inhalation product, available in two strengths, marks the first commercialised product from Aurobindo’s inhalation pipeline. The stock has gained 41.16% year-to-date in 2026.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Aurobindo Pharma (AUROPHARMA).
- Category: Stocks.
Why it matters
A routine update for Aurobindo Pharma. Use the price and stock snapshot to gauge how the market is responding.











